About: Comparison of the Elecsys® Anti-SARS-CoV-2 immunoassay with the EDI(TM) enzyme linked immunosorbent assays for the detection of SARS-CoV-2 antibodies in human plasma

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Comparison of the Elecsys® Anti-SARS-CoV-2 immunoassay with the EDI(TM) enzyme linked immunosorbent assays for the detection of SARS-CoV-2 antibodies in human plasma Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Comparison of the Elecsys® Anti-SARS-CoV-2 immunoassay with the EDI(TM) enzyme linked immunosorbent assays for the detection of SARS-CoV-2 antibodies in human plasma
Creator	Mueller, Thomas Austria, Bundschuh, C Bundschuh, Christian Clodi, M Clodi, Martin Dieplinger, Benjamin Egger, M Egger, Margot Gabriel, C Gabriel, Christian Linz, Linz, Ordensklinikum Mueller, T Schwestern, Barmherzige Wiesinger, K Wiesinger, Kurt
Source	Elsevier; Medline; PMC; WHO
abstract	BACKGROUND: Here, we report on a head-to-head comparison of the fully-automated Elecsys® Anti-SARS-CoV-2 immunoassay with the EDI(TM) enzyme linked immunosorbent assays (ELISA) for the detection of SARS-CoV-2 antibodies in human plasma. METHODS: SARS-CoV-2 antibodies were measured with the Elecsys® assay and the EDI(TM) ELISAs (IgM and IgG) in 64 SARS-CoV-2 RT-PCR confirmed COVID-19 patients with serial blood samples (n=104) collected at different time points from symptom onset. Blood samples from 200 healthy blood donors and 256 intensive care unit (ICU) patients collected before the COVID-19 outbreak were also used. RESULTS: In COVID-19 patients, the percentage of positive results rose with time from symptom onset, peaking to positivity rates after 15-22 days of 100% for the Elecsys® assay, of 94% for the EDI(TM) IgM-ELISA and of 100% for the EDI(TM) IgG ELISA. In the 104 blood samples, the agreement between positive/negative classifications of the Elecsys® assay and the EDI(TM) ELISAs (IgM or IgG) was 90%. The false positivity rates in the healthy blood donors and the ICU patients were <1% for the Elecsys® assay and <3% for the EDI(TM) ELISAs. CONCLUSIONS: Our results indicate a high sensitivity and specificity for the Elecsys® assay and an acceptable agreement with the EDI(TM) ELISAs.
has issue date	2020-05-30(xsd:dateTime)
bibo:doi	10.1016/j.cca.2020.05.049
bibo:pmid	32485155
has license	no-cc
sha1sum (hex)	4c9feec97a01248785c58b6d5536d64f7b73957d
schema:url	https://doi.org/10.1016/j.cca.2020.05.049
resource representing a document's title	Comparison of the Elecsys® Anti-SARS-CoV-2 immunoassay with the EDI(TM) enzyme linked immunosorbent assays for the detection of SARS-CoV-2 antibodies in human plasma
has PubMed Central identifier	PMC7261064
has PubMed identifier	32485155
schema:publication	Clin Chim Acta
resource representing a document's body	covid:4c9feec97a01248785c58b6d5536d64f7b73957d#body_text
is schema:about of	named entity 'DETECTION' covid:arg/4c9feec97a01248785c58b6d5536d64f7b73957d named entity 'https' named entity 'enzyme' named entity 'doi' named entity 'immunoassay' named entity 'human plasma' named entity 'SARS' named entity 'SARS-CoV-2' named entity 'IgG' named entity 'EDI' named entity 'ELISAs' named entity 'SARS-CoV-2' named entity 'e801' named entity 'protein' named entity 'IgG' named entity 'electrochemiluminescence' named entity 'IVD' named entity 'SARS-CoV-2' named entity 'coronavirus' named entity 'enzyme' named entity 'EDI' named entity 'plasma pool' named entity 'antibody' named entity 'Roche Diagnostics' named entity 'IgM' named entity 'antibody' named entity 'ELISAs' named entity 'intensive care' named entity 'CLSI' named entity 'ethics committee' named entity 'SARS-CoV-2' named entity 'high affinity' named entity 'IgM' named entity 'SARS-CoV-2' named entity 'COVID' named entity 'recombinant' named entity 'EDI' named entity 'blood donors' named entity 'cobas' named entity 'Switzerland' named entity 'reagent' named entity 'antibodies' named entity 'antibody response' named entity 'IgM' named entity 'EDI' named entity 'antibodies' named entity 'COVID' named entity 'immunoassay' named entity 'study protocol' named entity 'Roche Diagnostics' named entity 'Austria' named entity 'blood samples' named entity 'nucleocapsid protein' named entity 'IgG' named entity 'serological testing' named entity 'COVID-19' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'EDI' named entity 'RT-PCR' named entity 'COVID' named entity 'RT-PCR' named entity 'IgM' named entity 'Linz'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software